CD274 and cancer: Thus, immune checkpoint inhibitors (ICIs) against CTLA4 and PD-1 and its ligand PD-L1, such as Ipilimumab, Pembrolizumab, Nivolumab, and Atezolizumab, have been used to treat the malignant tumors and significantly improve the survival of patients (5–8).